Moderna COVID-19 vaccine receives full FDA approval for adults

Published



The Food and Drug Administration granted full approval to Moderna’s two-dose COVID-19 vaccine, marketed under the name Spikevax, more than a year after authorizing it for public use.

“The FDA’s approval of Spikevax is a significant step in the fight against the COVID-19 pandemic, marking the second vaccine approved to prevent COVID-19,” said acting FDA Commissioner Janet Woodcock. “The public can be assured that Spikevax meets the FDA’s high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States.”

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.